Five-year results from the Phase III NRG-GU003 clinical trial demonstrate that hypofractionated postprostatectomy radiotherapy (HYPORT)—delivering a shorter 25-fraction course of radiation—achieves biochemical control and patient-reported quality-of-life outcomes comparable to conventional … Read More
Patients with limited-stage small cell lung cancer reported better quality of life and less perceived inconvenience at three weeks when treated with once-daily higher-dose…
Australian researchers at the University of Adelaide have secured $240,000 in backing under a national initiative from the Mark Hughes Foundation Centre for Brain Cancer Research to investigate microscopic radiation … Read More
New federal and philanthropic funding totaling millions of dollars is accelerating pioneering research into brain cancer treatments, targeting aggressive malignancies like glioblastoma through novel approaches such as carbon dot technology … Read More
New guidelines issued by the American Society for Radiation Oncology (ASTRO) optimize the delivery of radiation therapy for pancreatic cancer patients. Published in August 2026, the updated clinical recommendations refine … Read More
Traditional pathological risk factors after prostate cancer surgery successfully identify patients with aggressive disease and worse prognoses, but they fail to predict who will benefit from adding hormone therapy to … Read More
